If you suffered losses exceeding $75,000 in Humacyte between May 10, 2024 and October 17, 2024 and would like to discuss your ...

New York, New York-- (Newsfile Corp. - November 29, 2024) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, ...

Humacyte, Inc. (NASDAQ:HUMA – Get Free Report) has been assigned a consensus rating of “Buy” from the eight research firms ...

On Wednesday, Humacyte Inc (HUMA) stock saw a decline, ending the day at $4.4 which represents a decrease of $-0.03 or -0.68% from the prior close of $4.43. The stock opened at $4.44 and touched a low ...

On Monday, Humacyte Inc (HUMA) stock saw a decline, ending the day at $4.28 which represents a decrease of $-0.21 or -4.68% from the prior close of $4.49. The stock opened at $4.47 and touched a low ...

SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Humacyte, Inc. (NASDAQ ...

DURHAM, N.C., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable ...

Humacyte (HUMA) has disclosed a new risk, in the Share Price & Shareholder Rights category. Humacyte is facing substantial ...

Humacyte ( (HUMA) ) has shared an announcement. Humacyte, Inc. has initiated a registered direct offering of approximately $30.0 million in common stock and warrants to an institutional investor.

NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Humacyte, Inc. (“Humacyte” or the “Company ...

When I first analyzed Humacyte in October 2022, its stock was trading at ~$4.65 a share and prospects looked encouraging for its then dubbed human acellular vessel (HAV) platform candidates.